Company news
NIOX Group PLC news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Price Monitoring Extension
June 17, 2019
Publication of Tudorza Phase IV ASCENT in JAMA
May 8, 2019
FDA approval of Duaklir for treatment of COPD
April 1, 2019
FDA website posts Duaklir NDA approval
March 29, 2019
Circassia announces FDA approval of Tudorza sNDA
March 29, 2019
Notice of Results
February 8, 2019
Successful FDA Presubmission Meeting for AirNOvent
February 4, 2019
Admission to AIM
February 4, 2019
Commercial rights acquired from AIT Therapeutics
January 24, 2019
General Meeting Business Update
January 4, 2019
Listing Rule 9.6.14(R) Disclosure
December 17, 2018
Option exercised for Tudorza from AstraZeneca
December 11, 2018
Posting of Shareholder Circular
December 10, 2018
Proposed admission to trading on AIM
December 10, 2018
Interim Results for Six Months Ended 30 June 2018
September 27, 2018
Notice of Interim Results and Broker Appointment
September 7, 2018
Director Declaration
August 16, 2018
Regulatory Application
August 13, 2018
Issue of Equity and Total Voting Rights
July 18, 2018
Publication of Circular
June 27, 2018
US Filing of Duaklir NDA & Tudorza Supplement NDA
June 1, 2018
Positive Data Presented at 2018 ATS Conference
May 22, 2018
Annual Financial Report and Notice of AGM
April 27, 2018
Issue of Equity - AstraZeneca
April 24, 2018
Receives Innovative Tech Contract from Vizient
February 8, 2018
Block Listing Six Monthly Return
January 17, 2018
TR-1: Notification of major holdings
January 8, 2018
Notification of Major Holdings
December 19, 2017
Tudorza® Meets Primary Endpoints in ASCENT Study
December 4, 2017
Circassia Welcomes New NICEAsthma Guidelines
November 29, 2017
Interim results six months ended 30 June 2017
September 27, 2017
European Launch of NIOX VERO® Nasal Mode
September 12, 2017
Primary Endpoints Met in AMPLIFY Phase III Study
September 7, 2017
Notice of Interim Results
August 24, 2017
Notification of Major Interest in Shares
June 29, 2017
Result of AGM 2017
May 26, 2017
Annual Report and Notice of Annual General Meeting
April 28, 2017
Non-Executive Director Retirements
April 25, 2017
Preliminary Results for Year Ended 31 Dec 2016
April 25, 2017
Top-Line Results of House Dust Mite Allergy Study
April 18, 2017
Completion of Transaction and Admission to Trading
April 12, 2017
Early Termination of HSR Waiting Period Granted
April 11, 2017
Result of General Meeting on 3 April 2017
April 3, 2017
Publication of a Prospectus
March 17, 2017
Collaboration with AstraZeneca
March 17, 2017
Interim Results
September 27, 2016
Block listing six monthly return
July 18, 2016
Top-Line Results from Cat Allergy Phase III Study
June 20, 2016
Grass Registration Study Initiation
May 25, 2016
Grant of awards to Directors
May 19, 2016